trial · primary record
Nadofaragene Firadenovec
Intermediate Risk Non-Muscle Invasive Bladder Cancer
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 454 |
| Primary completion | 2032-09-30 |
| Primary endpoint | Recurrence Free survival |
| Registry ID | NCT06510374 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:44:13.410Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06510374
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Nadofaragene Firadenovec · compound